Multiple SCLEROSIS. Demyelinating diseases of the central nervous system
Conditions
Interventions
Intervention 1: The experimental group received metacognitive therapy for eight weeks. Intervention 2: the control group spent the routine process of the sessions held by the MS Society.
Behavior
Treatment - Drugs
The experimental group received metacognitive therapy for eight weeks
the control group spent the routine process of the sessions held by the MS Society.
Sponsors
Investigator
Eligibility
Sex/Gender
Female
Age
30 Years to 40 Years
Inclusion criteria
Inclusion criteria: Main inclusion and exclusion criteria: Inclusion criteria: The final diagnosis of developing MS by the neurologist, signing a written consent form to participate in the study, having at least a diploma and achieving scores 1 to 4 in EDSS diagnosed by the neurologist. Exclusion criteria: Receiving psychological treatments at least six month prior to entering the study, a history of metabolic diseases like thyroid and absence of more than two sessions.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Metacognitive Components. Timepoint: pre test, Post test, two-step follow-up. Method of measurement: Metacognition Questionnaire -30 (MCQ-30).;Resiliency. Timepoint: pre test, Post test, two-step follow-up. Method of measurement: Connor and Davidson Resilience Scale (CD-RISC).;Self-Efficacy. Timepoint: pre test, Post test, two-step follow-up. Method of measurement: General Self-Efficacy Questionnaire.;Defense Mechanisms. Timepoint: pre test, Post test, two-step follow-up. Method of measurement: Defense Styles Questionnaire (DSQ). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Hossein Shareh
Hakim Sabzevari University
Outcome results
None listed